Inhibrx Biosciences INBX
NASDAQ INBX
$96.99 -0.94 (-0.96%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) Return on Capital Employed [ROCE] (2024 - 2026)

Updated

Inhibrx Biosciences (INBX) reported Return on Capital Employed [ROCE] of -101.62% for Q2 2026, down 12.99 percentage points from -88.63% a year earlier.

Analysis

Inhibrx Biosciences (INBX) Return on Capital Employed [ROCE] (2024 - 2026) Analysis & Trends

For FY2025, Inhibrx Biosciences posted Return on Capital Employed [ROCE] of -104.01%, up 58.79 percentage points from FY2024.

  • By year, Return on Capital Employed [ROCE] came in at -162.79% in FY2024.
  • Five-year quarterly Return on Capital Employed [ROCE] spans a low of -205.95% in Q4 2024 and a high of -88.63% in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 17.83%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 17.92%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 19.32%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.54%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 16.66%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 11.86%
10 Inhibrx Biosciences 1.43 Bn 1.43 Bn - -101.62%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -101.62%
Dec 31, 2025 -105.34%
Sep 30, 2025 -96.99%
Jun 30, 2025 -88.63%
Mar 31, 2025 -178.82%
Dec 31, 2024 -205.95%
Sep 30, 2024 -188.30%
API Access

Inhibrx Biosciences Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=INBX&period=max&api_key=YOUR_API_KEY